Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; A possible time relation

Prostate

Volumn 76, Issue 1, 2016, Pages 32-40

  Badrising, Sushil K ^a   Van Der Noort, Vincent ^a   Van Den Eertwegh, Alfons J M ^b   Hamberg, Paul ^c   Van Oort, Inge M ^d   Van Den Berg, Hendrik P ^e   Los, Maartje ^f   Aarts, Maureen J B ^g   Coenen, Jules L L M ^h   Gelderblom, Hans ⁱ   De Jong, Igle J ^j   Kerver, Emile D ^k   Vrijaldenhoven, Suzan ^l   Van Voorthuizen, Theo ^m   Warmerdam, Fabienne ⁿ   Haanen, John B ^a   Bergman, Andries M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Integraal Kankercentrum Rotterdam   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Nijmegen Medical Centre ^*  (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ISALA HOSPITAL   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF GRONINGEN   (Netherlands)

^k ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^l Medical Centre Alkmaar   (Netherlands)

^m RIJNSTATE HOSPITAL   (Netherlands)

ⁿ Zuyderland Medical Centre   (Netherlands)

more..

Author keywords

abiraterone; AR plasticity; cross resistance; docetaxel; enzalutamide; prostate cancer

Indexed keywords

ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; BLOOD; CANCER GRADING; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG MONITORING; DRUG RESISTANCE; DRUG SUBSTITUTION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; NETHERLANDS; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; ANDROSTENES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NETHERLANDS; PHENYLTHIOHYDANTOIN; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84955174733     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23094     Document Type: Article

References (24)

1. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
2. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,. COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
3. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim C-S, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin M-E, Venner PM, Tombal B,. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433.
5. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin M-E, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE,. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-160.
6. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M,. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 90: 2317-2325.
7. Badrising S, van der Noort, V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJM, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM,. Clinical activity and tolerability of enzalutamide ({MDV}3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014; 120: 968-975.
8. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS,. Antitumour activity of enzalutamide ({MDV}3100) in patients with metastatic castration-resistant prostate cancer ({CRPC}) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014; 50: 78-84.
9. Thomson D, Charnley N, Parikh O,. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer. Eur J Cancer 2014; 50: 1040-1041.
10. Schrader AJ, Boegemann M, Ohlmann C-H, Schnoeller TJ, Krabbe L-M, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E,., Cronauer MV,. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-36.
11. Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P,. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 2013; 48: 268-275.
12. Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J., Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: A multicentre analysis Eur Urol 2014; 68: 317-324.
13. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E,. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study. Eur Urol 2014; 68: 147-153.
14. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. JCO 2008; 26: 1148-1159.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. The R Core Team. R: A language and environment for statistical computing. R foundation for Statistical Computing [Internet]. R Foundation for Statistical Computing, Vienna, Austria; 2013. Available from: http://www.r-project.org.
17. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN,. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015; 67: 23-29.
18. EMA: Xtandi Summary of Product Characteristics. 2014; Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002639/WC500144996.pdf.
19. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA,. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109: 32-39.
20. Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T,. External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer. BMC Urol 2014; 14: 31.
21. Hamberg P, Verhagen PCMS, de Wit R,. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008; 44: 1193-1197.
22. Simmons MN, Stephenson AJ, Klein EA,. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007; 51: 1175-1184.
23. Yates C,. Prostate tumor cell plasticity: A consequence of the microenvironment. Adv Exp Med Biol 2011; 720: 81-90.
24. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL,. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.